1. Home
  2. AMTB vs PCRX Comparison

AMTB vs PCRX Comparison

Compare AMTB & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Amerant Bancorp Inc.

AMTB

Amerant Bancorp Inc.

HOLD

Current Price

$28.69

Market Cap

1.2B

Sector

Finance

ML Signal

HOLD

Logo Pacira BioSciences Inc.

PCRX

Pacira BioSciences Inc.

HOLD

Current Price

$24.67

Market Cap

949.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMTB
PCRX
Founded
1979
2006
Country
United States
United States
Employees
N/A
829
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
949.9M
IPO Year
2018
2010

Fundamental Metrics

Financial Performance
Metric
AMTB
PCRX
Price
$28.69
$24.67
Analyst Decision
Buy
Strong Buy
Analyst Count
3
4
Target Price
$23.67
$30.25
AVG Volume (30 Days)
436.0K
643.2K
Earning Date
04-23-2026
04-30-2026
Dividend Yield
1.57%
N/A
EPS Growth
386.36
107.44
EPS
0.97
0.19
Revenue
N/A
$541,533,000.00
Revenue This Year
$8.29
$6.78
Revenue Next Year
$7.67
$8.54
P/E Ratio
$29.32
$125.42
Revenue Growth
N/A
26.04
52 Week Low
$15.62
$18.80
52 Week High
$30.60
$27.66

Technical Indicators

Market Signals
Indicator
AMTB
PCRX
Relative Strength Index (RSI) 54.56 47.36
Support Level $21.68 $21.71
Resistance Level $30.60 $27.08
Average True Range (ATR) 0.63 0.97
MACD -0.25 -0.12
Stochastic Oscillator 21.47 32.34

Price Performance

Historical Comparison
AMTB
PCRX

About AMTB Amerant Bancorp Inc.

Amerant Bancorp Inc is a bank holding company. Through its bank, it provides individuals and businesses deposit, credit, investment, wealth management, and fiduciary services, both in the United States and to select international customers. The bank also provides banking services through traditional channels, such as banking centers and ATMs, as well as via secure websites, mobile devices and telephones.

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

Share on Social Networks: